Showing 1531-1540 of 2494 results for "".
- Implandata Wins Medica Innovation World Cup – 1st Place of 300 Digital Health Ventureshttps://modernod.com/news/implandata-wins-medica-innovation-world-cup-1st-place-of-300-digital-health-ventures/2480485/Implandata Ophthalmic Products was awarded 1st place at the
- Oxurion Enters Into a Capital Commitment of Up to €30 Million With Negma Grouphttps://modernod.com/news/oxurion-enters-into-a-capital-commitment-of-up-to-e30-million-with-negma-group/2479054/Oxurion announced that is has agreed to a capital commitment of up to €30 Million with Paris-based financial institution Negma Group. Negma Group has committed to subscribe to up to €30 million in equity in tranches over a 12-month period through mandatory convertible bonds at Oxurion’s sole dis
- Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technologyhttps://modernod.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/Eyenuk announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million. The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS,
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- Take Diabetes Into Consideration When Assessing for Glaucomahttps://modernod.com/news/take-diabetes-into-consideration-when-assessing-for-glaucoma/2476193/Diabetes and hyperglycemia are associated with thicker central corneal thickness (CCT), which could lead to overestimation of intraocular pressure when assessing patients for glaucoma, new research suggests, as reported by Medscape.
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- Orbis and Alcon to Kick Off Two-Week Training for Caribbean Eye Care Teams to Help Fight Avoidable Blindness in Local Communitieshttps://modernod.com/news/orbis-and-alcon-to-kick-off-two-week-training-for-caribbean-eye-care-teams-to-help-fight-avoidable-blindness-in-local-communities/2481016/On August 8, Orbis International, with support from Alcon, will kick off its first in-person training project on board the
- Permanent J Code Issued for Avedro’s Photrexa Drug Formulationshttps://modernod.com/news/permanent-j-code-issued-for-avedros-photrexa-drug-formulations/2479654/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific J code, J2787, for Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution). These Photrexa formulations are the onl
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co